SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 755.75+2.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic8/4/2017 4:36:05 PM
  Read Replies (1) of 3559
 
Did Sanofi made same mistake with Fasinumab, as it did with Eylea????
Well, 2Q both Teva and Mitsubish paid P3 milestone to REGN, indicating that after reviewing program (side effect incidence rate) they continue to express optimism. This program will cost them much more than $20-30 m milestone. So, Is Mr. Market right to neglect this program????

Pfizer is doing important P3 titration study ( clinicaltrials.gov ), results due to be reported by year-end.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News